Discrimination of HIV-2 infection from HIV-1 infection by western blot and radioimmunoprecipitation analysis.
Serum and plasma samples were collected from blood donors who were confirmed positive for antibodies to HIV-1 in the United States, and from blood donors and individuals in West Africa and Portugal who were positive for antibodies to HIV-1, HIV-2, or both. Western blots and sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) radioimmunoprecipitation assays (RIPA) utilizing native HIV-1 and HIV-2 proteins were performed on these specimens to determine the ability of these procedures to discriminate between HIV-1 and HIV-2 infections. Extensive serologic cross reactivity between HIV-1 and HIV-2 p24 was found in both populations. Antibody reactivity to the envelope protein gp120 was able to discriminate 20 of 20 (100%) U.S. specimens as HIV-1 infections. In specimens from West Africa and Portugal, Western blot and RIPA were in complete agreement on 33 of 42 samples (78.6%). Among these 33 specimens, 10 were found to be reactive for antibodies to HIV-1 only, 10 were reactive to HIV-2 only, and 13 were considered to be dually reactive, having antibodies reactive with both HIV-1 gp120 and HIV-2 gp120. Nine of the 42 specimens were discordant by Western blot and RIPA classification, being dually reactive by one procedure and reactive with only one viral gp120 by the other technique. Because of the serological cross reactivities between HIV-1 and HIV-2, in certain populations it is difficult to ascertain whether an individual is infected with HIV-1, HIV-2, a new viral type, or whether the individual is infected simultaneously with multiple viruses. More specific tests such as viral isolation or molecular probes may be necessary to distinguish between infections with these viruses in certain populations.
Holzer
T J
TJ
Abbott Laboratories, Experimental Biology Research, North Chicago, IL 60064.
Allen
R G
RG
Heynen
C A
CA
Kennedy
M M
MM
Knigge
M F
MF
Paul
D A
DA
Dawson
G J
GJ
D000163:Acquired Immunodeficiency Syndrome / Q000175:diagnosis*; D015153:Blotting, Western; D003937:Diagnosis, Differential; D004591:Electrophoresis, Polyacrylamide Gel; D015683:Gene Products, gag / Q000276:immunology; D015483:HIV Antibodies / Q000032:analysis*; D016655:HIV Core Protein p24; D015699:HIV Envelope Protein gp120 / Q000276:immunology; D015497:HIV-1 / Q000276:immunology*; D015498:HIV-2 / Q000276:immunology*; D006801:Humans; D011233:Precipitin Tests; D014758:Viral Core Proteins / Q000276:immunology
D015683:Gene Products, gag; D015483:HIV Antibodies; D016655:HIV Core Protein p24; D015699:HIV Envelope Protein gp120; D014758:Viral Core Proteins